четверг, 28 июля 2016 г.

Drug developer Kadmon skids following weak demand for IPO

Drug developer Kadmon skids following weak demand for IPO


Shares of drug developer Kadmon Holdings tumbled Wednesday after its initial public offering priced far below the company's estimates. Kadmon said its offering of 6.25 million shares priced at $12 a share, raising $75 million in total.



from Biotech News